Clinical Trials Logo

Filter by:
NCT ID: NCT04969263 Completed - Clinical trials for Kidney Transplant Recipients

COVID-19 Protection After Transplant Pilot Study

CPAT
Start date: August 10, 2021
Phase: Phase 2
Study type: Interventional

Antibodies are an important part of the body's defense against infection. Individuals who have no antibodies or very low antibody levels are considered less well protected from Coronavirus Disease 2019 (COVID-19) than those who have higher antibody levels. What level of antibodies is necessary for protection is currently unknown. Inadequate antibody response to Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) vaccination has been described among kidney transplant recipients. The aim of this study is to elicit an antibody response to vaccination against SARS-CoV-2 in kidney transplant recipients who have failed to respond to two doses of either the Moderna COVID-19 vaccine or Pfizer-BioNTech Coronavirus Disease 2019 (COVID-19) vaccine.

NCT ID: NCT04969250 Completed - Covid19 Clinical Trials

Vaccination for Recovered Inpatients With COVID-19 (VATICO)

Start date: August 25, 2021
Phase: Phase 4
Study type: Interventional

In this Phase 4, open-label trial, participants of the ACTIV-3/TICO clinical trial at selected sites who received certain pre-specified blinded investigational agents or placebo as part of that trial, and who have since achieved sustained recovery, and who are still [TICO assignment] blinded and who are still within 28 to 90 days after initial TICO randomization, will be randomized in this 2x2 factorial design to one of four groups: (i) immediate versus 12 week deferral of first dose administration and also (ii) one dose only, versus two doses to be given 4 weeks apart of the Moderna mRNA-1273 or the Pfizer BNT162b2 vaccine (mRNA vaccines). Choice of Moderna or Pfizer vaccine is determined based on availability at the site. The choice is individual, although participants vaccinated twice should receive the same type of vaccine for both injections. The primary objectives of this 2x2 factorial design are (i) to estimate the difference in neutralizing antibody (NAb) response to the mRNA vaccine from baseline to Week 48 among participants vaccinated early versus deferred, and (ii) to estimate the difference in NAb response to this vaccine among participants vaccinated once versus twice. The primary analyses will be carried out in participants randomized to placebo in TICO. Analyses will also be carried out for those who receive the investigational agent(s) studied in TICO. A key secondary objective is to ascertain the effect, if any, of SARS-CoV-2 monoclonal antibodies, and other interventions that have been studied in hospitalized COVID-19 subjects, on natural and vaccine-induced immunity. Participants will remain blinded to the interventions received in the ACTIV-3/TICO study, however allocation to the timing of vaccination and to one or two vaccinations in this (VATICO) study is not blinded.

NCT ID: NCT04969211 Completed - Healthy Clinical Trials

Bioequivalence Study Between VHX-896 Tablets and Iloperidone Tablets in Healthy Volunteers

Start date: June 30, 2021
Phase: Phase 1
Study type: Interventional

This is a single center, two-period, randomized study to evaluate the Bioequivalence of VHX-896 Tablets Relative to Iloperidone Tablets in Healthy Volunteers

NCT ID: NCT04969198 Completed - Tobacco Dependence Clinical Trials

UW Withdraw From Tobacco Study

Start date: July 13, 2021
Phase: Phase 2
Study type: Interventional

It is of considerable scientific and clinical importance to assess tobacco withdrawal accurately since withdrawal severity is highly determinant of smoking cessation success. In addition, smoking cessation pharmacotherapy produces its effects on smoking abstinence by suppressing such symptoms. However, in order to ensure that a measure of tobacco withdrawal is sensitive to severe withdrawal, it is essential to examine a period of unmedicated abstinence. The current study aims to validate, and possibly enhance, a revised Wisconsin Smoking Withdrawal Scale long and brief version for use in research and clinical settings. Two hundred adults who smoke cigarettes daily and report a desire to quit smoking will be enrolled. This is a treatment-delay, one-group clinical trial that is intended to enhance the assessment of tobacco withdrawal amongst participants who try to quit smoking with delayed use of cessation medication. Participants will not receive any pharmacotherapy during the first 1 week of their quit attempt and will initiate 8 weeks of combination nicotine replacement therapy (C-NRT; nicotine patch + nicotine mini-lozenge) starting 1 week past the target quit day (TQD). Participants will receive 4 counseling sessions as well (1 pre-quit, 3 post-quit). Participants will complete 4 weeks of ecological momentary assessment (EMA) smartphone surveys including a 2-week baseline (starting TQD-14) and 2-week post-TQD (1-week un-medicated, 1-week using C-NRT).

NCT ID: NCT04969003 Completed - Depression Clinical Trials

Reducing Transphobia Among Adolescents Through a Brief Video Intervention

Start date: March 1, 2022
Phase: N/A
Study type: Interventional

The purposes of this new study are to test among adolescent viewers the utility of brief video-based interventions to: 1. reduce transphobia; 2. reduce depression-related stigma and increase likelihood of treatment-seeking; and 3. examine the role of viewer's sex (male / female / non-binary), race (Black vs non-Black), and sexual orientation (straight vs LGBQ) as independent factors on the outcomes of interest.

NCT ID: NCT04968925 Completed - Visual Acuity Clinical Trials

Evaluation of Comfort for Two Marketed Daily Disposable Contact Lenses

Start date: July 12, 2021
Phase: N/A
Study type: Interventional

This study is a 2-phase adaptive approach utilizing a 2×2 crossover design. The study lenses will be worn in a bilateral fashion for a period of approximately 1-week each.

NCT ID: NCT04968912 Completed - Sjogren's Syndrome Clinical Trials

A Study of Nipocalimab in Adults With Primary Sjogren's Syndrome (pSS)

Start date: September 21, 2021
Phase: Phase 2
Study type: Interventional

The purpose of this study is to evaluate the efficacy and safety of nipocalimab in participants with primary Sjogren's syndrome (pSS) versus placebo.

NCT ID: NCT04968821 Completed - Clinical trials for Spinal Degenerative Disorder

Telehealth Activity Intervention After Lumbar Spine Surgery

PASS
Start date: June 28, 2021
Phase: N/A
Study type: Interventional

The overall objective of this randomized controlled study is to examine the preliminary efficacy of a physical activity intervention that includes wearable technology and remote physical therapist support in patients undergoing lumbar spine surgery. Patients will be randomized to receive 8 sessions of a telehealth physical activity intervention (n=30) or usual postoperative care (n=30). The Investigator's central hypothesis is that a postoperative telehealth physical activity intervention will lead to greater improvements in objective physical activity (primary outcome) and patient-reported physical function, disability, and pain (secondary outcomes) compared to usual care in patients undergoing lumbar spine surgery.

NCT ID: NCT04968782 Completed - Acute Appendicitis Clinical Trials

Appendicitis Choice of Treatment Study

Start date: July 12, 2021
Phase:
Study type: Observational

A longitudinal observational/survey study evaluating patient centered decision making in the choice of treatment for acute appendicitis. Survey evaluates patients experience with decision making and the types of decision support they receive.

NCT ID: NCT04968353 Completed - Clinical trials for Maxillary Lateral Incisor Malocclusion

Effect of Clear Aligner Attachment Design on Extrusion of Maxillary Lateral Incisors

Start date: August 1, 2021
Phase: N/A
Study type: Interventional

The purpose of this research is to test which of four clear aligner attachment types is more efficient in extruding (erupting) maxillary lateral incisors vertically into correct position during orthodontic treatment.